Humana (HUM) Stock
US health insurer with Medicare Advantage and care services. Here's the price, business snapshot, and what's worth knowing about Humana in August 2026.
Humana Inc (HUM) is a major US health insurance and services company, best known for its large Medicare Advantage business alongside commercial and Medicaid plans. With a market cap around $35.5bn, Humana generates revenues from premiums, care-management services and health-services initiatives that aim to lower costs and improve outcomes. Investors often watch Humana for its exposure to the growing Medicare Advantage market and its push into value-based care, primary-care partnerships and home health services, which can offer structural growth if executed well. Key considerations include reimbursement policy, regulatory oversight, medical-cost trends and membership retention. The stock can be sensitive to election-driven healthcare policy and short-term claims volatility. This summary is educational and not personalised investment advice; returns are not guaranteed and the value of investments can fall as well as rise. Consider your goals, risk tolerance and seek independent advice before investing.
Why It’s Moving
Humana is moving on improving cost trends, but guidance cuts keep the recovery story in focus.
- Morgan Stanley upgraded Humana to equal weight after noting improving cost trends, easing some investor concern around medical expenses and margin pressure.
- The company also drew attention after cutting its 2026 EPS outlook despite stronger quarterly results, highlighting that earnings quality is improving but near-term profitability remains under pressure.
- Recent updates around Medicaid leadership, Wisconsin contract wins, and home-care workforce initiatives suggest Humana is still actively reshaping its government-services business while investors watch execution closely.
Humana is moving on improving cost trends, but guidance cuts keep the recovery story in focus.
- Morgan Stanley upgraded Humana to equal weight after noting improving cost trends, easing some investor concern around medical expenses and margin pressure.
- The company also drew attention after cutting its 2026 EPS outlook despite stronger quarterly results, highlighting that earnings quality is improving but near-term profitability remains under pressure.
- Recent updates around Medicaid leadership, Wisconsin contract wins, and home-care workforce initiatives suggest Humana is still actively reshaping its government-services business while investors watch execution closely.
About This Stock
Humana
HUM
Current Price
$375.33
Potential 12 Month Profit
-5.45%
Sector
Healthcare
Industry
Healthcare Providers & Services
Ticker
HUM
Market Cap
$45.39B
Potential 12 Month Profit
-5.45%
Sector
Healthcare
Industry
Healthcare Providers & Services
Sixth Month Growth Performance
When is the next earnings date for Humana (HUM)?
Humana’s next earnings date is expected to be November 6, 2026, based on its current reporting schedule. The release should cover third-quarter 2026 results. If the company adjusts its timing, the date could shift slightly, but early November is the current expectation.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Humana's stock, believing it has potential for growth despite current prices.
Financial Health
Humana is performing well with strong revenue, cash flow, and good asset value per share.
Dividend
Humana's low dividend yield of 0.87% indicates limited dividend payouts. If you invested $1000, you would be paid $8.70 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Medicare Advantage Focus
Humana’s scale in Medicare Advantage can be a structural growth engine, though outcomes depend on policy and medical-cost trends.
Care-Delivery Push
Investors may watch its moves into value-based care and home health since these can improve margins over time, but execution risk remains.
Regulatory Sensitivity
Policy and reimbursement changes materially affect profits and membership; consider regulatory risk alongside growth opportunities.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.